Immucell (ICCC) Share-based Compensation (2010 - 2026)
Immucell's (ICCC) quarterly Share-based Compensation came in at $103781.0 in Q4 2025, up 50.71% YoY from $68863.0 in Q4 2024, and down 85.54% on a QoQ basis from $717859.0 in Q3 2025.
Immucell (ICCC) Share-based Compensation (2010 - 2026) Analysis & Trends
Immucell (ICCC) has 16 years of Share-based Compensation data on file, last reported at $103781.0 in Q4 2025.
- Quarterly Share-based Compensation rose 50.71% year-over-year to $103781.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $291573.0 (down 10.44% YoY) and the FY2025 annual result came in at $875883.0, up 139.89% from the prior year.
- Share-based Compensation slipped to $103781.0 in Q4 2025, from $717859.0 in the prior quarter.
- In the past five years, Share-based Compensation ranged from a high of $983878.0 in Q4 2022 to a low of $23265.0 in Q2 2021.
- A 5-year average of $148201.4 and a median of $76607.0 in 2023 frame the typical range for Share-based Compensation.
- Annual changes were most pronounced in 2022 — Share-based Compensation surged 2303.75% — and 2023, when it slumped 89.77%.
- Tracing ICCC's Share-based Compensation over 5 years: stood at $40931.0 in 2021, then surged by 2303.75% to $983878.0 in 2022, then tumbled by 89.77% to $100659.0 in 2023, then plunged by 31.59% to $68863.0 in 2024, then jumped by 50.71% to $103781.0 in 2025.
- The last three Share-based Compensation figures came in at $103781.0 (Q4 2025), $717859.0 (Q3 2025), and $66714.0 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.76 Bn | 130.91 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 86.15 Bn | 78.15 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 64.45 Bn | 59.27 Bn | 1.37 Bn | - |
| 4 | Moderna | 57.08 Bn | 51.94 Bn | 52.00 Mn | 120.00 Mn |
| 5 | BeOne Medicines | 42.08 Bn | 36.99 Bn | 1.53 Bn | 137.41 Mn |
| 6 | Alnylam Pharmaceuticals | 30.90 Bn | 27.59 Bn | 992.69 Mn | 86.63 Mn |
| 7 | BioNTech SE | 27.76 Bn | 9.37 Bn | 668.28 Mn | 28.05 Mn |
| 8 | Insmed | 27.45 Bn | 26.29 Bn | 358.27 Mn | 41.25 Mn |
| 9 | Royalty Pharma | 27.00 Bn | 26.17 Bn | - | - |
| 10 | Immucell | 95.12 Mn | 86.26 Mn | 2.44 Mn | 239,867.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 239,867.00 |
| Jun 30, 2026 | 239,867.00 |
| Dec 31, 2025 | 103,781.00 |
| Dec 31, 2025 | 103,781.00 |
| Sep 30, 2025 | 717,859.00 |
| Sep 30, 2025 | 717,859.00 |
| Jun 30, 2025 | 66,714.00 |
| Jun 30, 2025 | 66,714.00 |
| Mar 31, 2025 | 52,215.00 |
| Mar 31, 2025 | 52,215.00 |
| Dec 31, 2024 | 68,863.00 |
| Dec 31, 2024 | 68,863.00 |
| Sep 30, 2024 | 77,557.00 |
| Sep 30, 2024 | 77,557.00 |
| Jun 30, 2024 | 98,021.00 |
| Jun 30, 2024 | 98,021.00 |
| Mar 31, 2024 | 81,110.00 |
| Mar 31, 2024 | 81,110.00 |
| Dec 31, 2023 | 100,659.00 |
| Dec 31, 2023 | 100,659.00 |